Clene Nanomedicine
Biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | $7.3m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 251 % | (35 %) | 38 % | (48 %) | (28 %) | 2007 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (7770 %) | (6704 %) | (9529 %) | (7958 %) | (9497 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (9358 %) | (1347 %) | (6325 %) | (7569 %) | (11520 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 7381 % | 3930 % | 6748 % | 4076 % | 5865 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Clene Inc. is a clinical-stage biopharmaceutical company focused on developing innovative nanotherapeutics to address cellular energy impairments common in neurodegenerative diseases. The company operates in the biopharmaceutical market, primarily serving patients with conditions such as Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS). Clene's business model revolves around the development and commercialization of its proprietary nanocrystal-based therapies, with its lead drug candidate, CNM-Au8, currently in clinical trials. The company generates revenue through equity and debt financings, out-licensing of commercial-stage assets, and potential future sales of its therapeutic products. Clene aims to revolutionize the treatment landscape for neurodegenerative diseases by restoring and protecting neuronal health and function.
Keywords: nanotherapeutics, neurodegenerative diseases, cellular energy, biopharmaceutical, ALS, MS, clinical trials, CNM-Au8, nanocrystals, therapeutic development.